Serious adverse events · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80 mmHg or greater
It is very uncertain whether evening changes serious adverse events compared with morning dosing regimen (very low certainty).
1 finding from 1 review
Serious adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Phentermine/topiramate showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Naltrexone/bupropion showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Orlistat probably leads to higher serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · people with primary hypertension
It is very uncertain whether combination therapy changes serious adverse events compared with monotherapy (very low certainty).
1 finding from 1 review
Serious adverse events · people with primary hypertension
It is very uncertain whether combination with potassium‐sparing diuretics changes serious adverse events compared with monotherapy (very low certainty).
1 finding from 1 review
Total serious adverse events · patients with hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total serious adverse events · patients with hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total serious adverse events · patients with hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total serious adverse events · cardiovascular disease with high blood pressure
Lower blood pressure targets showed no clear difference in total serious adverse events compared with standard blood pressure targets (low certainty).
1 finding from 1 review
Total serious adverse events · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes total serious adverse events compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Other serious adverse events · adult patients with hypertension
Lower BP target may leads to higher other serious adverse events compared with standard BP target (low certainty).
1 finding from 1 review
RR 1.44 [1.32, 1.59]
Studies not reported
Low
Serious adverse events: cardiovascular events · older adults with primary hypertension
Higher BP target (< 150‐160/95‐105 mmHg) showed no clear difference in cardiovascular serious adverse events compared with lower BP target (< 140/90 mmHg) (low certainty).
1 finding from 1 review
Fatal or non‐fatal serious adverse events · people with primary hypertension
Renin inhibitors showed no clear difference in fatal or non‐fatal serious adverse events compared with ACE inhibitors (low certainty).
1 finding from 1 review
Intervention not reported
Total serious adverse events Systolic targets · Diabetes Mellitus with elevated blood pressure
The intervention showed no clear difference in total serious adverse events Systolic targets (low certainty).
1 finding from 1 review
Total serious adverse events Duration: 1.75 to 3 years · patients with hypertension
First‐line thiazides showed no clear difference in total serious adverse events Duration: 1.75 to 3 years compared with first‐line calcium channel blockers (low certainty).
1 finding from 1 review
Total serious adverse events№ of participants: 18165(6 RCTs) · adult patients with hypertension
Lower BP target showed no clear difference in total serious adverse events№ of participants: 18165(6 RCTs) compared with standard BP target (moderate certainty).
1 finding from 1 review
RR 1.04 [0.99, 1.08]
Studies not reported
Moderate